// App-Quantinova.ai

POS1022 (2021) : BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • R. B. Warren

  • C. T. Ritchlin

  • L. Gossec

  • J. F. Merola

  • D. Assudani

  • J. Coarse

  • B. Ink

  • I. Mcinnes

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • The University of Manchester, Dermatology Centre, Manchester NIHR Biomedical Research Centre, Manchester, United Kingdom

  • University of Rochester Medical Center, Rochester, United States of America

  • Sorbonne Universite and Pitie-Salpetriere Hospital, Rheumatology, Paris, France

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, United States of America

  • University of Glasgow, Human Nutrition, School of Medicine, Glasgow, United Kingdom

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Fas receptor

  • Malondialdehyde

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT02969525

  • NCT03347110

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved